Preventing Stroke: Anticoagulation and Atrial Fibrillation

9 episodes

1.25 program credits

1h 11m

Details

Episodes

Documents

Presenters

Comments

Overview
This educational program is designed to equip healthcare professionals (HCPs) with the knowledge and skills necessary to accurately identify and manage patients who have atrial fibrillation (AF), which increases the risk of ischemic stroke. The program aims to address the critical need for early screening, keep HCPs up-to-date with the latest advancements, and ensure personalized care in the management of anticoagulation therapy.
Target Audience
This activity has been designed to meet the educational needs of the interdisciplinary team, which includes cardiologist and internal medicine, as well as other healthcare providers involved in managing patients with Atrial Fibrillation and Venous Thromboembolism.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss appropriate diagnostic criteria and challenges faced in screening patients who may be at risk for blood clots due to either AF or VTE
- Identify appropriate candidates for oral anticoagulation when AF or VTE is detected
- Develop evidence-based, individualized treatment plans for patients with an indication for oral anticoagulation
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

The following faculty have disclosed:
Manesh R. Patel, MD, chair for this educational event, receives research funds from AstraZeneca, Bayer, Janssen, Mytonomy, and Procyrion; and receives consulting fees from Bayer, Janssen, and Novartis.

John H. Alexander, MD, MHS, faculty for this educational event, receives research funds from Artivion/CryoLife, Bayer, Bristol-Myers Squibb, CSL Behring, Ferring, U.S. FDA, Humacyte and US NIH; and receives consulting fees from AbbVie, Akros, Artivion/CryoLife, AtriCure, Bayer, Bristol-Myers Squibb, Ferring, GlaxoSmithKline, Janssen, Novostia, Pfizer, Portola, Theravance and Veralox.

Steve Deitelzweig, MD, MMM, SFHM, FACP, FACC, faculty for this educational event, receives research funds from BMS and Pfizer; and receives consulting fees from BMS, Pfizer and Bayer.

Christopher B. Granger, MD, faculty for this educational event, receives research grants or contracts from Alnylam Pharm., Boehringer Ingelheim, Bristol Myers Squibb, Duke Clinical Research Institute, FDA, Janssen Pharmaceutica Products, L.P., Lilly Pharmaceutical, Novartis Pharmaceutical Company, Pfizer, and Philips; receives consulting fees from Abbvie, Abiomed, Anthos., Bayer Corporation, Boehringer Ingelheim, Boston Scientific Corporation, Bristol Myers Squibb, Cardionomic, CeleCor Therapeutics, HengRui USA, Janssen Pharmaceutica Products, L.P., Medscape, LLC, Medtronic Inc., Merck, NephroSynergy, NIH, Novo Nordisk, Novartis Pharmaceutical Company, Pfizer, Philips, REATA, and Veralox Therapeutics, Inc; and has ownership interest in Tenac.io.

Tatjana Potpara, MD, PhD, FESC, faculty for this educational event, has no relevant financial relationships with ineligible companies.
Planners and Managers Disclosure List
The following planners/reviewers/managers have disclosed:

Vin Kalathiveetil, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

Total CME, LLC., planners and managers have no relevant commercial relationships to disclose.

All the relevant financial relationships for these individuals have been mitigated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Provider(s)/Educational Partner(s)
Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.
Commercial Support
This activity is supported by an independent educational grant from Pfizer Inc.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 01/19/2024
Expiration Date: 01/19/2025